First Time Loading...

ADC Therapeutics SA
NYSE:ADCT

Watchlist Manager
ADC Therapeutics SA Logo
ADC Therapeutics SA
NYSE:ADCT
Watchlist
Price: 4.96 USD 11.71%
Updated: Apr 18, 2024

ADC Therapeutics SA
Cost of Revenue

Last Value
3-Years CAGR
5-Years CAGR
Quarterly
Annual
TTM
|

ADC Therapeutics SA
Cost of Revenue Peer Comparison

Comparables:
ACIU
CRSP
BSLN
IDIA
KURN

Competitive Cost of Revenue Analysis
Latest Figures & CAGR of Competitors

Company Cost of Revenue CAGR 3Y CAGR 5Y CAGR 10Y
ADC Therapeutics SA
NYSE:ADCT
Cost of Revenue
$-2.5m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
AC Immune SA
NASDAQ:ACIU
Cost of Revenue
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
CRISPR Therapeutics AG
NASDAQ:CRSP
Cost of Revenue
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Basilea Pharmaceutica AG
SIX:BSLN
Cost of Revenue
CHf-26.8m
CAGR 3-Years
-4%
CAGR 5-Years
-6%
CAGR 10-Years
N/A
Idorsia Ltd
SIX:IDIA
Cost of Revenue
CHf-6.3m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Kuros Biosciences AG
SIX:KURN
Cost of Revenue
CHf-5.1m
CAGR 3-Years
-29%
CAGR 5-Years
-121%
CAGR 10-Years
N/A

See Also

What is ADC Therapeutics SA's Cost of Revenue?
Cost of Revenue
-2.5m USD

Based on the financial report for Dec 31, 2023, ADC Therapeutics SA's Cost of Revenue amounts to -2.5m USD.

What is ADC Therapeutics SA's Cost of Revenue growth rate?
Cost of Revenue CAGR 1Y
-20%

Over the last year, the Cost of Revenue growth was -20%.